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Background: Classical scrapie in sheep is a fatal neurodegenerative disease associated with the conversion PrPC to
PrPSc. Much is known about genetic susceptibility, uptake and dissemination of PrPSc in the body, but many aspects
of prion diseases are still unknown. Different proteomic techniques have been used during the last decade to
investigate differences in protein profiles between affected animals and healthy controls. We have investigated
the protein profiles in serum of sheep with scrapie and healthy controls by SELDI-TOF-MS and LC-MS/MS. Latent
Variable methods such as Principal Component Analysis, Partial Least Squares-Discriminant Analysis and Target
Projection methods were used to describe the MS data.
Results: The serum proteomic profiles showed variable differences between the groups both throughout the
incubation period and at the clinical end stage of scrapie. At the end stage, the target projection model separated
the two groups with a sensitivity of 97.8%, and serum amyloid A was identified as one of the protein peaks that
differed significantly between the groups.
Conclusions: At the clinical end stage of classical scrapie, ten SELDI peaks significantly discriminated the scrapie
group from the healthy controls. During the non-clinical incubation period, individual SELDI peaks were differently
expressed between the groups at different time points. Investigations of differences in -omic profiles can contribute
to new insights into the underlying disease processes and pathways, and advance our understanding of prion
diseases, but comparison and validation across laboratories is difficult and challenging.
Keywords: Scrapie, SELDI-TOF-MS, PCA, PLS-DA, Target projection, LC-MS/MS, Serum amyloid A, SheepBackground
Prion diseases, like scrapie in sheep, are often called
Transmissible Spongiform Encephalopathies (TSEs).
These are fatal neurodegenerative diseases in a variety of
host species, including humans. They are all associated
with the conversion of the normal host cellular prion
protein, PrPC, into the abnormal protease-resistant iso-
form, PrPSc. The PrP genotype influences susceptibility, in-
cubation period and clinical presentation, the V136R154Q171
allele being most highly associated with classical scrapie in
sheep. To control and prevent spread of scrapie, genetic
screening and breeding for resistance are widely used, and* Correspondence: Siv.Meling@nvh.no
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[1,2]. The PrP genotype is, however, neither a marker for
definitive disease, nor the only genetic factor influencing
prion diseases [3,4]. Despite the effort of reducing suscep-
tibility, and monitoring and culling of ruminants, scrapie
still exists [5,6].
As of today, much research into prion diseases has
evolved around the prion protein itself through infection
and dissemination studies, and relatively little has been
done on other non-PrPSc disease processes. The most
recent large scale survey on prevalent PrPSc in human
appendix samples in Britain, suggests a higher preva-
lence of infection than formerly anticipated, in all
human PrP genotypes, and these findings further neces-
sitates focusing on various mechanisms in prion disease
development and progression [7]. The variable incuba-
tion time, the complex epidemiology and differentLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
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logical picture are increasingly important to elucidate
[8-10]. Different -omic studies of tissues and body fluids,
like serum, may potentially reveal markers that can con-
tribute to unravel the intricate pathogenesis of prion
diseases. Recently, several non-PrPSc proteins have been
put forward as promising biomarkers for preclinical
scrapie [11-15]. Identification of such non-PrPSc bio-
markers may be crucial in future prion research.
The Surface Enhanced Laser Desorption/Ionization-
Time of Flight-Mass Spectrometry (SELDI-TOF-MS)
technology (Ciphergen Biosystems, Fremont, CA, USA)
was designed to perform a mass spectrometry (MS) ana-
lysis of protein mixtures based on the mass-to-charge
(m/z) ratio of the proteins, and on their binding affinity
to the various chip surfaces. For a single charged pro-
tein, the molecular weight in Dalton (Da) usually corre-
sponds well to the mass-to-charge (m/z) value, and the
peak intensity corresponds well to the concentration in
the sample. Different protein expression profiles may
then be determined from these protein profiles by com-
paring the intensity of peaks of similar m/z value [16].
Proteins are good indicators of current cellular func-
tions, and investigation into the serum proteome repre-
sents one direction in biomarker research [16]. One of
the challenges in investigating the serum proteome is its
complexity and the presence of high abundant blood
proteins, particularly albumin. It is estimated that the
high abundant proteins constitute 95% of the bulk mass
of proteins, but they represent less than 0,1% of the total
number of proteins [17]. These high abundant proteins
may produce large signals and mask or interfere with
the detection of other low abundant proteins [18]. To
simplify the sample complexity, an up-front fraction-
ation procedure is recommended in addition to the frac-
tionation achieved by the chromatographic properties of
the SELDI ProteinChip® Array technology [16,19,20].
Extracting crucial information from the retrieved mass
spectrometry (MS) data can be challenging. These data
often have a much higher number of variables compared
to number of samples, they do not follow a normal
distribution, there is heteroscedasticity and variables are
highly correlated. For these reasons, much effort has
been invested in finding reliable methods to assist the inter-
pretation of such profiles. Machine learning methods repre-
sent one direction, and another is the latent variable (LV)
approach where principal component analysis (PCA) is
commonly used for unsupervised exploratory analysis of
mass spectral data [21]. Partial least squares discriminant
analysis (PLS-DA) is another method that utilizes the
knowledge of group belonging to identify discriminating
group data [22]. A problem with PLS-DA is that usually
numerous latent variables are needed in order to achieve
good discrimination between the groups and this can createinterpretation problems. Following up with target projec-
tion (TP) method, the axis of best discrimination between
groups can be achieved, and interpretation on a single
predictive latent variable is obtained [23]. Rajalahti et al.
developed a quantitative display called selectivity ratio (SR)
plot for selecting biomarkers in spectral profiles. The SR
plots provide both ranking and an objective measure of
probability to guide the investigator in the selection
process, resulting in a specific protein fingerprint profile
that classifies unknown samples into controls or infected
group [23,24]. It has been suggested that it is possible to
classify samples based on multiple biomarker patterns, and
therefore not constrained by the sensitivity and specificity
of any single biomarker [16,20,25].
In this work, SELDI-TOF-MS technology was used in
the analysis of pre-fractionated serum samples, and we
describe the data processing steps and the following
latent variable projection methods used to visualize the
variation and highlight variables which separate the
groups in question.
Results
Animals
At time of euthanasia, 23 weeks post inoculation (wpi),
all the scrapie infected animals showed typical signs of
scrapie, such as pruritus, ataxia, reduced live weight,
weak coordination and poor wool quality. None of the
animals in the control group showed any clinical signs
of scrapie. Brain material from both groups and inocula-
tion material used were examined by western blot (WB)
for the presence of PrPSc, and results are presented in
Figure 1.
SELDI-TOF-MS data processing and evaluation
Reproducibility of the SELDI-TOF MS analysis was eval-
uated on the basis of the calculated coefficient of vari-
ation (CV) of peak intensities and m/z. The pooled CVs
(CVp) were calculated and results are in the same region
as reported by others, and are shown in Table 1. CVp
for mass accuracy across samples were all below 1%.
Data analysis of clinical end stage data
PCA analysis was performed on MS data from both
end-stage study (ES) and longitudinal study (LS) on the
basis of peak clusters derived from biomarker wizard
feature (BW) included in the Ciphergen ProteinChip®
Software, and score plots are presented in Figures 2 and
3 respectively.
The PCA analysis was used solely for visualisation
purpose. The score plots in Figure 3 demonstrated that
the healthy animals and infected animals segregated well
at the clinical end-stage (23 weeks p.i.), but poorly dur-
ing the asymptomatic incubation period. Principal com-
ponent one (PC 1) describes most of the variation in
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Figure 1 Detection of PrPSc by Western blotting. WB using P4 antibody of homogenated brain material from animals and inoculation material
used in this experiment. Lanes 1–5 (2006 and 2007) represent the scrapie inoculated animals. Lanes 6–10 (2006) and 6–7 (2007) represent the
control animals. The lanes indicated by the arrow represent inoculation material used in the scrapie groups. Molecular markers were placed in
lanes 12 and 9. PrPSc was detected in inoculation material and in all the animals from the scrapie groups.
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accounted for by scrapie is unknown, as this method
does not take group belongings into account. Data sets
from LS were not analysed any further with LV methods,
due to the low number of peaks selected in BW, making
these methods not suitable. The LS data was furtherTable 1 Coefficient of variation for peak intensities
across samples (ES data) and quality control (QC)
sample (LS data)
Sample ID CVp%
1 20.5
2 14.8
3 12.6
4 22.6
5 23.4
6 28.0
7 16.9
10 15.6
11 26.1
12 25.4
13 14.1
14 14.8
15 28.7
19 19.4
20 16.8
21 15.8
22 18.4
23 28.6
24 28.6
QC 28.2
Statistical description of the CVp calculated for each of the individual sample
and QC sample. All the calculated CVp’s for peak intensities were below 28.7%
which was in the same region as others have reported [19,25,28,29].analysed by the non-parametric Mann–Whitney U test
for significant difference in individual peak intensity be-
tween the groups at each sampling time. The resulting
peaks and their m/z value, significance level and fold
change are listed in Table 2.
Only data from clinical end stage study was further
analysed by PLS-DA using group classification as the
dependent variable. Five (5) components were shown to
possess predictive information according to cross valid-
ation. This model used 70.6% of the variables in theFigure 2 Principle component analysis of 38 peak clusters from
end stage study (ES) data. Samples from scrapie affected animals
are indicated in red, and healthy controls are indicated in blue. The
first principal component explains 33% and second principal
component explains 18.3% of total variation in data. Both these
components visually separated the groups, and much of disease
related variation contributed on first (PC 1) and second (PC2)
principal components.
Figure 3 Principle component analysis of longitudinal study (LS) data. Samples from scrapie group are indicated in red, and samples from
control group are indicated in blue. One PCA plot for each sample point; six, eight, ten, 12, 14, 16, 18, 20, 22 and 23 weeks of age/post infection.
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Table 2 Significant peaks in the longitudinal study and fold change
Weeks of age/post infection
m/z 6 8 10 12 14 16 18 20 22 23
2030 ↓(1,9)** ↓(1,7)*
4395 ↓(5,9)***
4635 ↑(1,9)*** ↓(1,3)** ↑(1,3)* ↑(1,4)** ↑(2,1)***
5061 ↑(2,0)**
5201 ↓(4,4)**
5695 ↓(2,4)*** ↓(1,7)** ↓(1,5)*
5712 ↓(2,2)*** ↓(1,7)** ↑(1,5)*
7542 ↓(3,3)***
8057 ↓(5,7)**
8509 ↑(3,8)** ↑(4,3)*** ↑(3,1)***
8625 ↓(1,8)*
8724 ↑(3,2)**
8779 ↓(7,8)***
8796 ↓(1,9)** ↓(2,6)*** ↓(4,4)***
8813 ↓(1,7)** ↓(1,2)* ↓(2,5)*** ↓(3,2)***
9271 ↑(1,9)** ↓(1,7)* ↓(1,4)* ↑(1,3)** ↑(1,4)* ↑(2,4)***
9478 ↑(2,0)*** ↓(1,6)* ↓(1,3)** ↑(1,5)*
15073 ↑(27,2)*** ↓(6,5)***
15278 ↓(6,0)***
16106 ↑(19,7)*** ↓(5,9)**
Peaks found to be significantly under- and overexpressed in the scrapie group. Arrow indicates change in scrapie group relative to control group at different time
points post infection (weeks of age/post infection). ↓ - under-expression, ↑ - over-expression, m/z – mass in Dalton, average fold change in expression is given in
brackets. * = p < 0.05, ** = p < 0.01, *** = p < 0.001.
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97.8% of the variance in group membership (response
variable), indicating an excellent predictive model. This
PLS-DA model was used as the basis for the TP model
and the resulting TP scores are graphically presented in
Figure 4, showing excellent discrimination between
healthy controls and infected animals. The TP model
uses only 19.7% of the variables in protein profiles to ex-
plain the same 97.8% of the variance in the group mem-
bership. This indicates that most of the variation in the
mass spectral data was not related to the disease status,
and therefore removed in the TP model. The two models
are summarized in Table 3. By choosing 80% mean cor-
rect classification rate (MCCR) for the Mean Wilcoxon
Rank Sum as the sensitivity threshold for selecting dis-
criminating peaks, the Discriminating Variable (DIVA)
plot indicated the corresponding Selectivity Ration (SR)
threshold to be 0.41 (Figure 5). From this we were able
to select ten variables, presented in the Selectivity Ratio
Plot in Figure 6, with individual Wilcoxon classification
rate (sensitivity) in the range of 82 – 95 per cent
(Table 4). These ten peaks were used in a new PCA
analysis for a visual impression of the distribution of
animals on the basis of these ten peaks, Figure 7. Asillustrated in this PCA Score Plot, the two groups were
well separated along PC 1 which indicated that these ten
variables were highly related to group differences, i.e.
scrapie versus healthy. The intensity and standard devi-
ation of each of these SELDI peaks represented by m/z
value were plotted in a bar diagram and presented in
Figure 8. From this we can see that all of these ten pro-
teins were over-expressed at the clinical end stage of
scrapie.
Protein identification
Serum Amyloid A (SAA) protein (gi1173354) was identi-
fied by eight peptides using high confidence filter, giving
coverage of 45.54%, and SAA was only identified in the
scrapie sample. The peptide sequence of SAA and the
identified peptides are shown in Figure 9. SAA consists
of 112 amino acids and has a theoretical molecular
weight of 12 688 Da which corresponded well with one
of the selected SELDI peaks with an m/z of 12 682. The
data of this SELDI peak are presented in Table 5.
Discussion
In this study, we have evaluated the use of SELDI-MS-
TOF data and latent variable methods to create and
Figure 4 Target Projection score indicating grouping for each sample. All the scrapie samples (red) have a positive score value, and all the
samples from healthy controls (blue) have a negative score value. The samples are indicated on the x-axis, and the target projection score on the
y-axis. The TP model was able to separate the two groups with no misclassifications.
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healthy sheep from sheep with scrapie at various stages
during the incubation period and at the clinical end-
stage. Batxelli-Molina et al. discriminated sheep with
early phase scrapie and healthy controls by the use of
four SELDI peaks with sensitivity and specificity of
87.3% and 88.1%, respectively [11]. We were able to cre-
ate a good predictive regression model only from the
clinical end stage data, and based on ten peaks, to dis-
criminate scrapie affected animals from controls with a
sensitivity of 87.8%. One of these ten selected SELDI
peaks had a relatively high intensity in the scrapie group
and was barely detectable in the control group. This
peak had a mass (m/z) of 12 682 Da and a mean sensi-
tivity of 95%. Based on results from LS-MS/MS analysis
of samples from both control groups and scrapie groups,
this peak was identified as serum amyloid A (SAA). The
finding corresponds well with our previously published
data on quantitative measurement of SAA in serum
samples from these animals [26].
A range of different univariate and multivariate data
analysis methods and different software have been used
for analysing SELDI spectral data [11,16,17,19,25,27-30].
We believe that multivariate methods based on latentTable 3 Modelling results of both PLS-DA and TP predictive m
Data No. of spectra No. of PLS comp R2 (XPLS-DA)% R2 (XTP
C/S 88 5 70.6 19.7
C/Sa 88 4 91.1 48.6
No. of spectra: 19 individuals in 3–5 replicates; R2 (XPLS-DA): 70.6% of total varianc
is explained in the TP model; R2(y): 97.8% of total variance in the response variable
selected peaks with percentage of total peak selection in brackets; C/Sa: modellingvariables are better suited, as these methods can handle
data with more variables than observations and data
which are noisy and highly collinear [22,31,32]. They
provide a good tool for visualization of the data, detec-
tion of patterns and object classification. Latent variable
models reduce dimensionality of the data and reveal
the underlying concept and structure in them. These
methods have been reported by others to produce good
results from SELDI-TOF MS data [27]. However, due to
the few peaks (variables) in datasets from the longitu-
dinal study, we were not able to create a predictive
model without increasing risk of over-fitting the regres-
sion model. We were not able to define valid compo-
nents in the PLS-DA model and at the same time
achieve satisfactory cross validation of data. Results from
the longitudinal study were therefore only evaluated
visually by the PCA method, and individual peaks were
evaluated for significance through Mann Whitney U test.
Although significant p-values were observed at each
sampling time, these results should be interpreted with
care due to poor reproducibility of the SELDI-TOF-MS
analysis and the risk of false positives due to the
“multiple comparisons problem” arising when a high
number of peaks are independently compared between theodels before and after peak selection
)% R2(y)% % MCCR (DIVA) SR limit No. of selected peaks
97.8 80 0.41 10 (26%)
87.8
e in X is explained in the PLS-DA model; R2 (XTP): 19.7% of total variance in X
. y. is explained in both models; MCCR: mean correct classification rate; No. of
results after reduction of subset to only include the selected peaks.
Figure 5 DIVA plot. A DIVA plot of the TP model with the red solid line indicating mean Wilcoxon classification rate and standard deviation
(dashed line), and SR values on the x-axis. Horizontal line indicates the chosen 80% MWCR, and the vertical line indicating the resultant SR
threshold of 0.41.
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visualization, but it is an unsupervised method in-
cluding all variance in the data into the analysis, and
does not use any a priori information regarding
group membership [32]. Much of this variance may
also be due to other non-scrapie related differences
between the animals such as sex, age, genetics, sam-
pling time and individual physiological factors. Im-
portant biomarker patterns in serum proteome may
be buried under such major differences and by using
methods taking group membership into account,Figure 6 Selectivity Ratio plot for all peaks in the model. A bar chart o
(y-axis). The two horizontal lines indicate the SR threshold with an absolutedisease relevant differences may become clear. We
have illustrated this by using PLS-DA to analyse ES
data, where the model focuses on maximum separ-
ation of the two groups, in contrast to maximum
variation in the PCA model [22,33]. PLS-DA model
gives rise to large numbers of PLS components
required to describe the majority of the variation in
the data, and by combining these PLS components
into a single TP component, which represents the
direction in the multivariate predictive space with
strongest relation to the response, interpretationf all the peaks (x-axis) used in the model and their calculated SR value
value of 0.41. Ten peaks have a SR value above this threshold.
Table 4 Selectivity ratio value, Wilcoxon classification
rate and univariate p-value for each of the selected
variable
Variable
(m/z)
SR % Wilcoxon
Classification Rate
Mann–Whitney U test
p-value
4286 0.62 92 0.00E + 00
4629 0.94 94 0.00E + 00
5054 0.82 92 0.00E + 00
6338 1.60 94 0.00E + 00
6691 0.46 95 0.00E + 00
7628 0.48 84 3.87E-08
9258 0.68 87 1.50E-09
9464 0.99 95 0.00E + 00
12682 1.44 95 0.00E + 00
15474 0.46 82 1.78E-07
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ation to group membership has then been removed,
and the TP score vector displays the discriminative in-
formation between the two groups on a single scale.
This is illustrated and summarised in Table 3, where
we show that total variance in data used to describe
the predictive model was reduced to 19.7% in the TP
model, from 70.6% in the PLS-DA model. The TP
model also provides a quantitative measure of each ori-
ginal variable’s contribution to the discrimination be-
tween groups, but as peaks with large variance and
little correlation to group membership may dominateFigure 7 PCA plot of distribution of the two groups using only
ten peaks. The ten peaks selected from the analysis were used in a
PCA plot and there was good visual separation of the groups with
PC1 accounting for about 60% of the variation in the dataset based
on these ten peaks.over peaks with little variance and high correlation to
group membership, this could not directly be used to
select interesting peaks [34]. The selectivity ratio (SR)
for each variable on the TP component is directly re-
lated to each variable’s ability to predict group mem-
bership and this was used to select variables in the
model [23,24].
As described by Rajalahti et al., a sensitivity level, or
correct classification rate, for a set of peaks can be
chosen individually for each data set and this is done
statistically by the non-parametric Wilcoxon Rank Sum
test. Completely random classification with equal num-
ber of samples in each group then gives a correct classi-
fication rate of 50%, and correct classification of all the
samples will have a CR of 100% [23,24]. Setting the sen-
sitivity threshold must balance the risk between selecting
false biomarkers and missing important ones. In this
study, we chose a mean sensitivity level/correct classifi-
cation rate of 80% for the selected variables which gave a
selectivity ratio (SR) value of 0.41, this is illustrated in
the DIVA plot in Figure 5. Further on, this SR value was
applied to all the variables in the Selectivity Ratio plot,
Figure 6, and ten SELDI peaks qualified for selection by
having a SR value above this threshold.
For two-group comparisons, like in this work, receiver
operating characteristics (ROC) curves could be used to
compare the sensitivity and specificity of a biomarker
candidate at different cut-off values for peak intensity [36].
But as correct classification rate is identical to the sensitiv-
ity in a binary classification it will give us the same picture,
only that the DIVA plot expands into the multivariate
space.
The ten selected SELDI peaks were used in a PCA plot
in Figure 7 to illustrate how well they separated the two
groups in question along the PC 1. Figure 8 illustrates
the intensity of these ten peaks in the SELDI spectra,
and the increased expression in the scrapie group com-
pared to the control group is probably related to the
clinical status of the animals.
One of these peaks, with the m/z of 12682 Da, was
identified by LC-MS/MS as serum amyloid A (SAA),
which is a major acute phase protein (APP) in sheep. It
has been quite common to identify acute phase proteins
as discriminating biomarkers between groups of affected
and not affected individuals, as these are highly sensitive
reactants produced in response to an insult [18]. They
are, however, not very specific, although different insults
may produce different patterns of acute phase response
(APR). Many of the reported diagnostic SELDI peaks
have been found to be acute phase proteins, and are de-
scribed in several reviews [11,19,37,38]. SAA is primarily
induced by pro-inflammatory cytokines such as IL-1β,
TNF-α and IL-6, which are released by a variety of
cells including activated tissue macrophages and blood
Figure 8 The mean peak intensity and standard deviation for the ten selected peaks. A bar chart of the ten selectee peaks, with m/z on
the x-axis and intensity on y-axis. Scrapie samples were indicated in red, and controls were blue. Standard deviation for each mean was indicated
on each of the bars.
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ural scrapie, and mice with experimental scrapie, show
reactive astrocytosis and microglia activation and in-
creased cytokine expression in the brain at the time of
clinical signs and neuropathological changes [41-43].
These cytokines can cross over into the blood and initi-
ate a systemic APR with increased synthesis of APPs
from hepatocytes, such as SAA [44]. Coe et al. reported
an increased level of serum amyloid P in plasma of mice
with scrapie as evidence for systemic inflammatory re-
sponse to scrapie [45]. Batxelli-Molina et al. identified
transthyretin as being under-expressed in sheep with
clinical scrapie [11]. Transthyretin is a negative APP
expressed at lower levels during an APR along with the
other negative APPs. Although identification of APPs as
biomarkers of disease has not been considered signifi-
cant, we believe that identification of any protein, re-
gardless of specificity that significantly differs between
scrapie affected and healthy controls, will contribute to
novel information of underlying pathological processes
of scrapie. The long incubation period, large variety in
clinical presentation, as well as lack of direct link be-
tween neuropathology, PrPSc dissemination and clinical
presentation, create the need for new knowledge of
underlying processes at all stages of scrapie. Identifica-
tion of discriminating proteins will contribute in this
matter.Figure 9 SAA sequence and the identified peptides. Here is the total o
LC-MS/MS are highlighted. The peptide in red was identified with low con
and the peptides in green were identified with high confidence.The SELDI-TOF-MS may be an excellent tool for pro-
tein profiling due to its high throughput, but, as this
work has shown, there are too many technical limita-
tions resulting in lack of peak identification and poor re-
producibility to make this the technique of choice in the
search for specific biomarkers. The challenges and limi-
tations associated with SELDI-TOF-MS are nicely
reflected by the poor reproducibility between our longi-
tudinal and end point studies, and the low number of
peaks detected at some time points, like 10 and 18 weeks.
The method failed to detect the peak with m/z 12 kDa
at both ES and LS, even though this peak separated the
groups well and had high intensity in the ES study. Even
though there are a number of peaks found to be signifi-
cantly under- and overexpressed in the scrapie group
compared to the control group in the LS data, the
findings are of limited value, as long as the peaks are not
identified as specific proteins which can elucidate
specific pathological pathways of processes. It is also un-
certain whether these individual peaks are separate pro-
teins, several peaks can represent the same protein with
different charges or modifications. We also noticed that
there were large differences between the different time
points, even though all the samples included in the LS
were run randomly at the same time. This could be
due to introduction of variables during handling and
pre-processing of samples, especially from the initialvine Serum Amyloid A protein sequence and peptides identified by
fidence, the peptide in yellow was identified with medium confidence,
Table 5 Results from data analysis for SELDI peak with m/z of 12682
Peak
m/z
SR Mean Intensity –
Control
Standard Deviation
– Control
Mean Intensity –
Scrapie
Standard Deviation
– Scrapie
% Wilcoxon
Classification Rate
Mann–Whitney U
test p-value
12682 1.44 0.24 0.16 12.20 7.21 95 0.00E + 00
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detected in each group could be due to suspected vari-
ation in quality and quantity in the FT fraction. As
pointed out also by Van Gorp et al., many promising
studies on discriminating SELDI peaks have been pub-
lished, but few follow-up papers on peak identification
and validation have been published [46]. Barr et al.
actually proposed a protein fingerprint for TSE infection
in blood [47].
To create a proteomic profile able to detect sheep in-
fected with scrapie during the incubation period with
high sensitivity and specificity, rigorous testing of a large
number of animals would be necessary, in addition to
eliminating variability through sample handling and ana-
lytical procedures. In addition to scrapie, other neuro-
logical diseases would have to be similarly mapped. The
reproducibility and validity of discriminating proteomic
profiles would need to be confirmed across different la-
boratories and animal groups, including different geno-
types, scrapie strains and age groups. One of the major
limiting factors of SELDI proteomic profiles is the lack
of direct comparisons of SELDI peaks based solely on
m/z. Differences in experimental set-up from animal
model to data analysis result in poor reproducibility in
number of peaks detected, peak height and m/z, making
the resultant peak list incomparable [48]. Comparison of
SELDI data from different sample sets, different runs on
the same or across SELDI-TOF-MS instrument(s) have
resulted in considerable variation in number of discrim-
inating peaks [37]. Comparisons made across different
studies may also be misleading, as one protein species
can generate about ten major peaks and many minor
satellite peaks due to chemical reactions that may take
place during the sample preparation and analysis. Pro-
teins with approximately the same mass will show up
with overlapping peaks, and spectra obtained with differ-
ent machine settings can look different [49]. Our results
also confirm this problem, as the samples set for LS and
ES were prepared and analysed on two different occa-
sions, and we were not able to reproduce the exact same
results in the end point data sets. The relatively high
CVp seen for peak intensity both within and between
runs, indicate that slight changes in peak intensity be-
tween groups may not indicate an actual difference be-
tween groups, and thus careful interpretation of results
was necessary. This problem may be overcome by con-
siderably increasing the number of animals in each
group. Results across different age-groups were not
compared, as natural changes in protein profiles relatedto age changes may overshadow the difference due to
disease status. We worked with very similar groups to
enhance differences relating to scrapie, and minimize
differences related to pre-analytical factors like age, sex,
production status and genotype. The variance attributed
to pre-analytical factors was also minimized by one
normalization step before peak selection, and not two
as proposed by Poon (2007), due to the risk of intro-
ducing “false” differences between profiles by this renor-
malization [11,19,27,50]. The difficulty in identification
of proteins that correspond to the SELDI peaks is, as
mentioned earlier, another major limiting factor, as also
mentioned by Batxelli-Molina et al. and much effort
should be made to identify these discriminating proteins,
especially those which are significantly different between
the groups [11].
Conclusion
In conclusion, on the basis of the experimental infection
model used, including route of infection and PrP geno-
type of the animals, we believe that the results in this
study are relevant to the study of several aspects of nat-
urally infected classical scrapie cases. Choosing peaks/
proteins in biomarker research based solely on p-values
from univariate models may, however, result in a num-
ber of false markers, and latent variable methods are
much more suitable for these types of data. Such
methods are simple to use for non-statistical users, and
interpretation is made easy as results are visually well
presented. This article describes one approach, from ani-
mal model to data analysis, and the resulting selection of
significant protein peaks and creation of a predictive
model. The results show that it is possible to use data
from SELDI-TOF-MS in combination with multivariate
data analysis to discriminate scrapie affected sheep from
healthy controls. We identified one peak, or one dis-
criminating protein, to be serum amyloid A (SAA), in
the scrapie affected animals at the end stage. However,
the practical application of this predictive model is re-
stricted due to the limiting factors of SELDI-TOF MS.
The multiple detected differences between these groups
might, therefore, have been more completely illustrated
by other -omic methods. Studies on differences in prote-
omic profiles between healthy and scrapie infected sheep
will, undoubtedly, provide novel insight into the under-
lying pathogenic and pathological events. However, as
long as these discriminating protein peaks remain un-
identified, the pathological and clinical relevance of the
actual proteins in relation to scrapie remains unknown.
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sitive and specific bioassays using identified biomarkers,
obtained by –omic methods, which can be utilized by
various research groups across experiments.
Materials and methods
Animals
A total of 19 lambs over two consecutive years (2006
and 2007) were included in this study, all having the
same PrP genotype, homozygous V136R154Q171 (Table 6).
Lambs were inoculated orally with 1 gram homogenated
pooled brain material from either healthy sheep or con-
firmed cases of classical scrapie immediately after birth
and before any ingestion of colostrum and then grouped
(control or scrapie group) according to inoculation ma-
terial. Inoculation brain material used in both groups
was tested for PrPSc by WB (Figure 1). The lambs were
left with their mothers in confined isolated boxes under
similar conditions and feeding regimes. All the lambs
used were born within a time period of 15 days. At post
mortem examination, the obex area of the brain from
each animal was sampled for detection of PrPSc by WB
(Figure 1). Animal experiments were approved by the
Norwegian Animal Research Authority.
Serum samples
Serum samples used in this work were drawn every two
weeks from six weeks post infection (p.i.) until euthan-
asia in 2007 for the longitudinal study (LS). Serum sam-
ples at time of euthanasia from both 2006 and 2007
were used for the end-stage study (ES). Serum samples
were allowed to clot at room temperature for a mini-
mum of 30 minutes and maximum 60 minutes, and then
processed. Serum was pipetted in aliquots and frozen at
minus 80 degrees within two hours of sampling. All the
samples were subjected to the same handling procedures
throughout the experiment.
Serum fractionation
Serum samples were fractionated prior to SELDI-TOF
MS analysis, using strong anion exchange fractionation
kit, ProteinChip® Q Spin Columns (Bio-Rad), containing
Q ceramic HyperD F sorbent. Before application to col-
umns, proteins were denatured by addition of 150 μl
9 M Urea 2% Chapters 50 mM Tris–HCl pH 9 (U9) buffer
to each of the 100 μl of serum samples, this followed byTable 6 Overview over samples, animals, genotype and age o
Sample ID Year Group G
1, 2, 10, 11, 19 2006 Control V
5, 13, 14, 22 2007 Control V
3, 4, 12, 20, 21 2006 Scrapie V
6, 7, 15, 23, 24 2007 Scrapie Van additional 250 μl 1 M Urea 0,2% Chapters 50 mM
Tris–HCl pH 9 (U1) buffer. The 500 μl serum mixture
was added to the columns, and incubation time was set to
30 minutes at 4 degrees on a rotator to ensure complete
mixing of serum mixture and column sorbent. Each sam-
ple was fractionated into six fractions (FT/F1, F2, F3, F4,
F5 and F6). Flow through (FT) fraction was captured di-
rectly after sample incubation, and the consecutive frac-
tions were captured after adding washing buffers with
decreasing pH, starting at pH 9 and ending at pH 3 when
capturing F5. The last fraction, F6, was captured after a
wash with an organic buffer. The different fractions were
aliquoted, and stored at – 80°C soon after capture until
further analysis.
SELDI-TOF MS analysis
A Weak cation exchange array (ProteinChip® CM10
Array, Bio-Rad) in combination with high stringency
buffer, 50 mM HEPES pH 7.0 as binding and washing
buffer was used to analyse the flow through (FT) frac-
tion in this work. Each FT fraction was diluted 1:10 with
binding buffer before application to array, and each
individual LS and ES sample was applied randomly
onto the array in three and five replicates, respectively.
The matrix, ProteinChip® Sinapinic Acid (SPA) Energy
Absorbing Molecules (EAM), was applied before the
SELDI-TOF-MS analysis. The arrays were prepared and
handled according to manufacturer’s instructions. The
arrays were analysed on the Protein Biology System
II (PBS-IIc) with autoloader (Bio-Rad Laboratories)
using Ciphergen ProteinChip® Software Version 3.2.1.
(ProteinChip® Software) with the integrated Biomarker
WizardTM (BW) cluster analyses software [51]. Each
chip was analysed with a spot protocol optimized for the
low mass area (LM) between 2 and 25 kDa, and spectra
were collected using an average of 130 laser shots. ES and
LS samples were prepared and analysed separately. The
BW feature of the ProteinChip® Software was used for peak
clustering in the range of interest (2 kDa – 25 kDa).
Data processing
Spectral data was processed to reduce instrumental and
handling artefacts, minimize variation within groups and
maximize variation between groups, and improve peak de-
tection. Spectra were named and organised into groups
according to age at sampling and group belonging (controlf sampling at end stage of disease
enotype Sex Age in weeks
RQ/VRQ Male and Female 24 – 25
RQ/VRQ Male and Female 25
RQ/VRQ Male and Female 23
RQ/VRQ Male and Female 23 – 24
Table 7 High and medium confidence peptide filter
settings
Charge (z) XCorr Score XCorr Score
High confidence Medium confidence
1 1.2 0.7
2 1.9 0.8
3 2.3 1.0
> = 4 2.6 1.2
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Software [51]. This process involved four steps; calibration,
baseline subtraction, filtering and noise reduction and
normalization (TIC). Finally, peak selection was performed
by BW. Data processing was performed following recom-
mendations described by Bio-Rad [36]. The collected peak
data was exported into Microsoft® Office Excel 2003 and
Sirius Version 8.1 (Pattern Recognition System AS, Bergen,
Norway) for further data analyses. The spectra were evalu-
ated for intra-cassette and inter-cassette reproducibility by
calculation of the coefficient of variation (CV) for both
peak intensity and peak mass (m/z). The CV for ES data set
was calculated for each of the samples based on peak infor-
mation in each of the five replicates, and CV for LS data set
was calculated from peak information in a quality control
(QC) sample that was repeatedly run with the samples.
A calibration equation was created using the calibra-
tion feature in the ProteinChip® Software and standards
containing peptides and proteins of known mass (Pro-
teinChip All-In-One Peptide/Protein Standard, Bio-Rad),
which were run parallel to the samples. One equation
for each data set, ES and LS, was calculated and applied
to all the spectra in each of the respective study.
The shape of the baseline of each spectrum was exam-
ined and the baseline feature was used to subtract base-
line. Fitting width was set to two times (2×) expected
peak width. The noise range was set to 2 kDa to exclude
matrix attenuation range from the analysis, and end was
set to 100% of spectrum size.
The baseline and noise reduced spectra were normalized
using the Total Ion Count (TIC) Normalization feature
in the ProteinChip® Software, which normalizes each
spectrum to equal sum detected signal under the curve
in the region of interest. Each group, based on age and
group belonging was normalized separately. The result-
ing normalization factor created for each spectrum was
inspected and evaluated. Spectra with normalization
factor above mean + 2 standard deviations were ex-
cluded from further analysis.
Peak clusters were generated using the BW function in
the ProteinChip® Software to detect peaks of similar
mass across the spectra. Peaks were detected using the
following settings; first-pass detection with signal-to-
noise ratio > 5, with cluster completion using a second-
pass with signal-to-noise ratio > 2. The peaks needed to
be present in at least 20% of the spectra (giving a pres-
ence in at least half of each group). A mass difference of
0.3% was allowed. Peak cluster information was exported
to Excel for further analysis.
Data analysis
Univariate
The data were tested for difference in relative peak
intensity between the two groups using the non-parametric Mann–Whitney U test included in the BW
and Sirius software. The fold change in intensity was
calculated as the mean peak intensity control/mean
peak intensity scrapie for significantly down-regulated
peaks, and vice-versa for up-regulated peaks. For all
tests, the significance level was set to p < 0.05.
Multivariate
Latent variable projection methods (LV) were used to ana-
lyse the SELDI-TOF-MS data. Both ES and LS data was
analysed by principal component analysis (PCA) to visually
evaluate the distribution of the data irrespectively of group
belonging. Only ES data were further analysed using other
LV methods. A group membership variable was defined,
assigning “0” to all the samples in the control group, and
“1” to all the members in the scrapie group. Partial least
squares – Discriminant Analysis (PLS-DA) and target pro-
jection method (TP) were then used to evaluate the data
distribution according to group membership. For all ana-
lyses, the spectral variables were standardized to unit vari-
ance, thereby preventing variables with high variance to
dominate the data analysis. A non-parametric Discriminat-
ing Variable test (DIVA) was used to connect Selectivity Ra-
tio (SR) value to the discriminatory ability of the variables,
quantified as the probability of correct classification. Each
variable got a correct classification rate (CR), i.e. how well
each variable separated the two groups in question. The SR
value was plotted against the Mean Wilcoxon Rank Sum
Rate to obtain the DIVA plot.
Cross validation was used for ES data to optimize the
LV models with respect to predictive performance.
Different procedures for cross validation have been de-
veloped [52]. The ES data were split into four groups,
constructing one PLS model for each group, one group
was used as validation set and the others as training sets.
The number of PLS components was chosen as the one
giving the first minimum in prediction error.
Protein identification
One ES sample from each of the groups was prepared
and processed for protein identification. Thirteen μl of
the FT fraction were mixed with 6 μl 4× LDS, 2.5 μl 10×
DTT. The sample mixture was heated to 60°C for 15 -
minutes. 2.5 μl IAA (60 mM) was added to the mix and
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in the dark before loading on a 16% ClearPAGE gel (C.B.
S. Scientific, USA). The gel was run at 150 V for 85 -
minutes. After electrophoresis the gel was stained with
Gelcode Blue Safe Stain (Pierce, USA) for 1 hour and
de-stained overnight with ultrapure water. Three protein
bands in the region of 9 and 14 kDa bands on the gel
were excised and subjected to tryptic digestion using
OMX tube devices (OMX, Germany) following the
manufacturer’s protocol.
Tryptic peptide samples were sent to International Re-
search Institute in Stavanger (IRIS), Mekjarvik, Norway,
and protein identification was done according their stan-
dard operating procedure. The protein identification was
performed by LC-MS/MS analysis using an UltiMate 3000
dual pump nanoflow HPLC system (Dionex, Sunnyvale,
CA, USA) connected to a linear ion trap-Orbitrap mass
spectrometer (LTQ-Orbitrap XL, Thermo Fisher Scien-
tific, Waltham, MA, USA). A sample volume of 5 μl
from each sample was loaded onto a trapping column
(Acclaim PepMap100 C18, 5 μm, 300 μm I.D. × 5 mm
length, Dionex) at a flow rate of 2 μl/min in 0.1% formic
acid (VWR) in MilliQ water (Elga) for clean-up and
pre-concentration. Peptides were separated in the ana-
lytical column (Acclaim PepMap100 C18, 3 μm, 75 μm
I.D. × 15 cm length, Dionex). The mobile phases for the
analytical separation consisted of 0.1% formic acid in
2.5%/97.5% acetonitrile/water (A) and 0.1% formic acid
in 80%/20% acetonitrile/water (B) and were pumped
with a flow of 300 nL/min. The peptides were separated
on the analytical column using a linear gradient from 5
to 60% B in 165 min after a 10 min delay post injection.
The gradient was then run to 100% B in 10 min and held
there for 30 min to wash the columns. A total run time
of 256 min was used, including the washing step and
30 min re-equilibration of the columns. A PicoTip emit-
ter (SilicaTip, New Objective) with a 10 μm tip and with-
out coating was used as an ESI interface. The electrospray
voltage was set to 1 kV, and no sheath gas was used. The
mass spectrometer was used in positive mode. Full scans
were performed in the Orbitrap in the m/z range from
200 to 2000, and data-dependent MS/MS scans per-
formed in the linear ion trap for the five most abundant
masses with z ≥ 2 and intensity ≥10000 counts. Dynamic
exclusion was used with 3 min of exclusion after fragmen-
tation of a given m/z value four times. Collision-induced
dissociation (CID) was used with a collision energy of 35%
and with activation Q setting of 0.400 and activation time
of 30 ms for MS2. The mass spectrometer was tuned daily
and calibrated weekly using the calibration solution recom-
mended by Thermo Scientific.
Each LTQ-Orbitrap raw file was analysed using the
Proteome Discoverer 1.0 (Thermo Fisher Scientific). Pro-
tein identifications were performed with the SEQUESTalgorithm searching against even toed ungulate database
available at NCBI with trypsin as digestion enzyme, and
allowing for maximum two missed cleavage sites. Carbami-
domethyl (C) was set as a static modification, and oxidation
(M) as a dynamic modification. Precursor ion and fragment
ion mass tolerances were set to 10 ppm and 0.8 Da,
respectively. Results were filtered for minimum 2 peptides
and using a high and medium significance XCorr Score
adjusted for peptide charges (z), Table 7.
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